Digital healthcare is a proactive method to healthcare that drives numerous consumer touchpoints by way of genuine-time channels, so prospects can make properly-informed alternatives and make far better habits, eventually top to a far better excellent of life. This is precisely what Wellthy Therapeutics, a digital therapeutics firm with a presence in Asia and Europe, is working towards.
This digital therapeutics firm was established by people today with wealthy encounter in the overall health market, who had witnessed the gaps present in the course of action of treating chronic situations like diabetes or hypertension. Both the co-founders’ parents had also been managing chronic situations, which gave Abhishek Shah (CEO) and Prayat Shah (vice-president) a private viewpoint on the state of healthcare.
The overarching target was to catalyse the evolution of the healthcare space from the regular approach of episodic care—patient interactions only in the course of doctor visits or hospital stays—to continual care which can be accomplished by enabling situation-distinct, clinically validated digital infrastructure which, in turn, permits healthcare to do more for the patient.
“A major part of continual care would be giving the patient more power to leverage the toolkit in her hands to manage her conditions and seek help if it is required—something that Wellthy Therapeutics focuses on,” says Shah. “By allowing people to become accountable and actively tackle their condition, the platform would change the face of outcomes and ultimately lead to better outcomes.”
Wellthy Therapeutics focuses on how far better patient outcomes can be translated into far better financial outcomes for all stakeholders by way of a decrease price of hospitalisation, fewer ER visits, and more productivity. With exceptional overall health outcomes, Wellthy Therapeutics inspires and enables patients to reverse, manage or stop chronic situations such as Type-2 Diabetes, hypertension, women’s overall health, and so on.
Living up to its initial driving believed, Wellthy Therapeutics has been making patient-focused clinically validated options for its healthcare partners. By plugging in its options at distinctive stages of the patient journey, Wellthy Therapeutics then shares a fraction of the new income based on verified outcomes by means of a B2B2C channel. It also aids pharmaceutical and healthcare device firms with Real World Evidence, to boost overall health and financial outcomes.
The company’s digital therapeutics platform, Wellthy Care, aids to stop, handle or treat complicated clinical situations by working closely with pharmaceutical firms, healthcare devices, life insurers, overall health insurers, and healthcare systems to obtain genuine-planet clinical and enterprise outcomes across numerous therapeutic regions.
The platform has witnessed constant development more than the previous 5 years, forging partnerships with leaders of the healthcare ecosystem, like Roche, Intas, Cipla, and more. The DTx platform is at the moment live in 636 cities worldwide, operating in 4 key languages.
On the back of its exceptional worth proposition that bridges glaring gaps in the healthcare space, Wellthy Therapeutics has received $8,500,000 from numerous investors such as Cipla, Family Office of the founder of Manipal Hospitals + Manipal Cigna, Saama Capital, Beenext Ventures, GrowX Ventures, Bayer Pharma AG. The platform’s newest round of funding was completed in April 2020.
Headquartered in Mumbai with a base in Bengaluru, Wellthy Therapeutics has partnered with top players from pharma, overall health insurance coverage, healthcare devices, and hospitals.